ArticleThe oncologist2025

Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis.

Ke Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.